查看文章

To the Editors, Optimizing currently available monoclonal antibodies for the treatment of inflammatory bowel disease (IBD) requires a better understanding of factors affecting their pharmacokinetics and pharmacodynamics. 1 Throughout the long experience with antitumor necrosis factor (anti-TNF) biologics, several pharmacogenetic variants have been associated with increased risk of immunogenicity, accelerated clearance, and subsequent loss of response (LOR). 2–4 By contrast, little is known about the association of such pharmacogenetic determinants with the pharmacokinetics of ustekinumab and vedolizumab. 5

We therefore read with interest the post hoc analysis of the IM-UNITI and UNIFI cohorts, in which the authors investigated whether carriage of the human leukocyte antigen (HLA)-DQA1* 05 allele is associated with increased risk of immunogenicity, lower ustekinumab trough concentrations, and LOR …